Immunic Inc(IMUX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:43 PM ET (Korea 10/31 06:43)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.81 | Insider Own | 6.52% | Shs Outstand | 13.6M | Perf Week | 1.35% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 33.98% | Insider Trans | - | Shs Float | 12.8M | Perf Month | -13.08% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -0.93 | Inst Own | 74.5% | Short Float | 14.59% | Perf Quarter | -46.74% |
| Income | -0.11B | P/S | - | EPS this Y | 42.02% | Inst Trans | 14.19% | Short Ratio | 5.61 | Perf Half Y | -22.18% |
| Sales | 0.00B | P/B | 0.8 | EPS next 5Y | 27.02% | ROA | -101.15% | Short Interest | 1.86M | Perf YTD | 40.72% |
| Book/sh | 9.35 | P/C | 0.66 | EPS past 3/5Y | 45.16% 25.99% | ROE | -138.17% | 52W High | -56.91% ($17.43) | Perf Year | -4.23% |
| Cash/sh | 11.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -87.22% | 52W Low | 48.36% ($5.06) | Perf 3Y | -26.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.66% | Gross Margin | - | Volatility(W/M) | 7% 8.98% | Perf 5Y | -91.94% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.65 | Perf 10Y | -99.66% |
| Dividend Ex-Date | - | Quick Ratio | 5.05 | EPS Q/Q | 60.47% | Profit Margin | - | RSI (14) | 40.27 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.05 | Sales Q/Q | - | SMA20 | 0.45% ($7.48) | Beta | 1.47 | Target Price | $43.09 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -26.73% ($10.25) | Rel Volume | 0.74 | Prev Close | $7.8 |
| Employees | 92 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 31.32% - | SMA200 | -34.68% ($11.5) | Avg Volume(3M) | 0.33M | Price | $7.51 |
| IPO | 2014/4/17 | Option/Short | Yes/Yes | Trades | 2572 | Volume | 244,110 | Change | -3.66% |
🧬 Immuneering (IMUX) is a US Nasdaq-listed company that develops innovative oral new drugs targeting neurological and gastrointestinal diseases, operating as a late-stage biotech company. Its lead candidate, Bidofludimus Calcium, anchors a multiple sclerosis treatment pipeline, and the company positions itself as a clinical-stage pharmaceutical firm with strengths in oral dosing convenience and a differentiated mechanism of action.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
IMUX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +42.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 74.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #351 of 595 in the industry
Based on market cap of $102M.
FAQ
What kind of company is IMUX?
IMUX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMUX?
The market cap of IMUX is approximately $102M, ranking 4,445 within its sector.
What is the 52-week high and low for IMUX?
IMUX has recorded a 52-week high of $17.43 and a low of $5.06.
